The impact of calcineurin inhibitors on graft survival

Transplantation Reviews

Volumn 27, Issue 3, 2013, Pages 93-95

  Rush, David ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VOCLOSPORIN;

ADVERSE OUTCOME; ANURIA; ATROPHY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG MEGADOSE; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HYALINE DEGENERATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; T LYMPHOCYTE;

EID: 84880135766     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2013.04.003     Document Type: Review

References (34)

1. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1983, 309:809-815. The Canadian Multicentre Transplant Study Group.
2. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at 3years. N Engl J Med 1986, 314:1219-1225. The Canadian Multicentre Transplant Study Group.
3. Calne R.Y., White D.J., Thiru S., et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978, 2:1323-1327.
4. Webster A., Woodroffe R.C., Taylor R.S., et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005, 19. CD003961.
5. Busque S., Cantarovich M., Mulgaonkar S., et al. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am J Transplant 2011, 11:2675-2684.
6. Calne R.Y., Rolles K., White D., et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979, 2:1033-1036.
7. Myers B.D., Ross J., Newton L., et al. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984, 311:699-705.
8. Myers B.D., Sibley R., Newton L., et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988, 33:590-600.
9. Ojo A.O., Held P.J., Port F.K., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003, 349:931-940.
10. Nankivell B.J., Borrows R.J., Fung C.L., et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003, 349:2326-2333.
11. Racusen L.C., Colvin R.B., Solez K., et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003, 3:708-714.
12. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996, 61:1029-1037. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
13. Mathew T.H. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998, 65:1450-1454.
14. Oberbauer R., Segoloni G., Campistol J.M., et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48months after transplantation. Rapamune Maintenance Regimen Study Group. Transpl Int 2005, 18:22-28.
15. Vincenti F., Larsen C., Durrbach A., et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005, 353:770-781.
16. Rush D., Nickerson P., Gough J., et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998, 9:2129-2134.
17. Nickerson P., Jeffery J., Gough J., et al. The effect of increasing baseline immunosuppression on the prevalence of clinical and subclinical rejection: a pilot study. J Am Soc Nephrol 1999, 10:1801-1805.
18. Kurtkoti J., Sakhuja V., Sud K., et al. The utility of 1- and 3-month protocol biopsies on renal allograft function: a randomized controlled study. Am J Transplant 2008, 8:317-323.
19. Rush D., Arlen D., Boucher A., et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant 2007, 7:2538-2545.
20. Rush D., Cockfield S.M., Nickerson P.W., et al. Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetil. Transplantation 2009, 88:897-903.
21. Heilman R.L., Devarapalli Y., Chakkera H.A., et al. Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients. Am J Transplant 2010, 10:563-570.
22. Cosio F.G., Grande J.P., Wadei H., et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005, 5:2464-2472.
23. Park W.D., Griffin M.D., Cornell L.D., et al. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010, 21:1987-1997.
24. Gago M., Cornell L.D., Kremers W.K., et al. Kidney allograft inflammation and fibrosis, causes and consequences. Am J Transplant 2012, 12:1199-1207.
25. Stegall M.D., Park W.D., Larson T.S., et al. The histology of solitary renal allografts at 1 and 5years after transplantation. Am J Transplant 2011, 11:698-707.
26. Gourishankar S., Leduc R., Connett J., et al. Pathological and clinical characterization of the 'troubled transplant': data from the DeKAF study. Am J Transplant 2010, 10:324-330.
27. Mannon R.B., Matas A.J., Grande J., et al. Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. Am J Transplant 2010, 10:2066-2073.
28. Matas A.J., Leduc R., Rush D., et al. Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study. Am J Transplant 2010, 10:315-323.
29. Gaston R.S., Cecka J.M., Kasiske B.L., et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010, 90:68-74.
30. Hidalgo L.G., Campbell P.M., Sis B., et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009, 9:2532-2541.
31. Loupy A., Hill G.S., Suberbielle C., et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011, 11:56-65.
32. Wiebe C., Gibson I.W., Blydt-Hansen T.D., et al. Evolution and clinical pathological correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012, 12:1157-1167.
33. Ho J., Wiebe C., Rush D.N., et al. Increased urinary CCL2: Cr ratio at 6months is associated with late renal allograft loss. Transplantation 2013, 95:595-602.
34. El-Zoghby Z.M., Stegall M.D., Lager D.J., et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009, 9:527-535.